CSCO expert consensus on the diagnosis and treatment of breast cancer brain metastasis

Tao Wang,Jiayi Chen,Jin Yang,Minjie Fu,Wei Hua,Wang Jia,Yueping Liu,Biyun Wang,Min Yan,Juan Zhou,Chunfang Hao,Jiaxin Chen,Dan Ou,Tao Jiang,Ying Mao,Zefei Jiang,

DOI: https://doi.org/10.21037/tbcr-22-30

2022-07-01

Translational Breast Cancer Research

Abstract:CSCO expert consensus on the diagnosis and treatment of breast cancer brain metastasis

What problem does this paper attempt to address?

Factors Prognostic for Brain Metastases from Colorectal Cancer: A Single-Center Experience in China.

Da Wang,Chao Chen,Xiaoxu Ge,Qi Yang,Yuhuai Huang,Tianyi Ling,Tian Jin,Shaojun Yu,Jian Wang,Lifeng Sun

DOI: https://doi.org/10.2147/cmar.s320179

2021-01-01

Cancer Management and Research

Abstract:PURPOSE:This study aimed to analyze clinicopathological, survival, prognostic factors, as well as the timing of brain metastases (BM) in colorectal cancer (CRC) using data from a Chinese center.PATIENTS AND METHODS:Data of 65 consecutive CRC patients with BM were collected from a single institution in China. The time from primary tumor surgery to the occurrence of BM was calculated. Kaplan-Meier analysis was used to evaluate cumulative survival of patients. Factors associated with prognosis of overall survival (OS) were explored using Cox's proportional hazard regression models.RESULTS:The median time interval from CRC surgery to the diagnosis of BM was 24 months. After diagnosis of BM, median OS values for patients were 11 months. Extracranial metastases occurred in 45 cases (69.2%) when BM was diagnosed, and 58.5% of these patients with lung metastases Time of BMs (P=0.018), presence of extracranial metastases (P=0.033), treatment (P=0.003), CA199 (P=0.034), CA125 (P<0.001), CA242 (P=0.018), and CA211 (P=0.012) were associated with OS of patients through univariate analysis. Multivariate analysis using a Cox regression model showed that only treatment was an independent predictor for OS (conservative treatment; HR=1.861, 95% CI=1.077-3.441; P=0.048).CONCLUSION:Surgical treatment of metastatic lesions may be an alternative choice for CRC patients with BM. Identifying the timing of brain metastases can help to detect this disease early, leading to a better survival outcome.
Chinese expert consensus statement on the clinical diagnosis and treatment of breast cancer bone metastasis and bone related disease

Zefei Jiang,Haibo Wang,Shu Wang,Shusen Wang,Tao Wang,Xiaojia Wang,Jifeng Feng,Jian Liu,Qiang Liu,Tao Sun,Min Yan,Qingyuan Zhang,Jiayi Chen,Quchang Ouyang,Xichun Hu,Cuizhi Geng,Peng Yuan,Yongmei Yin,Ning Liao,Yueyin Pan

DOI: https://doi.org/10.21037/tbcr-20-65

2021-01-01

Translational Breast Cancer Research

Abstract:Chinese expert consensus statement on the clinical diagnosis and treatment of breast cancer bone metastasis and bone related disease
Chinese expert consensus on the clinical diagnosis and treatment of advanced breast cancer (2018)

Binghe Xu,Xichun Hu,Jifeng Feng,Cuizhi Geng,Feng Jin,Hongyuan Li,Man Li,Qing Li,Ning Liao,Donggeng Liu,Jian Liu,Qiang Liu,Jinsong Lu,Zhenzhen Liu,Fei Ma,Quchang Ouyang,Yueyin Pan,Kunwei Shen,Tao Sun,Yuee Teng,Zhongsheng Tong,Biyun Wang,Haibo Wang,Shulian Wang,Shusen Wang,Tao Wang,Xiang Wang,Xiaojia Wang,Yongsheng Wang,Zhonghua Wang,Jiong Wu,Min Yan,Junlan Yang,Yongmei Yin,Peng Yuan,Jin Zhang,Pin Zhang,Qingyuan Zhang,Hong Zheng

DOI: https://doi.org/10.1002/cncr.32832

IF: 6.9209

2020-07-25

Cancer

Abstract:<p>Breast cancer is the most common malignant tumor among women in the world. In 2005, there were approximately 272,000 new cases diagnosed and more than 70,000 deaths from breast cancer in China. Of the patients who are newly diagnosed with breast cancer each year, approximately 3% to 10% have distant metastases at the time of diagnosis. Of those who have early stage disease at diagnosis, from 30% to 40% will develop advanced breast cancer. The 5‐year survival rate for patients with advanced breast cancer is only 20%, and the median overall survival (OS) is 2 to 3 years. Although advanced breast cancer is still difficult to cure, physicians can relieve clinical symptoms, improve quality of life, and further prolong survival through the development of new drugs and the optimization model of treatment. Patients with advanced breast cancer have their own preferences in the choice of treatment options. Moreover, there is no standard recommendation for the treatment of refractory breast cancer after multiline therapy. To offer a reference for clinicians, a Chinese expert group has analyzed, summarized, and discussed related research data on the diagnosis, treatment, and prognosis of inoperable, locally advanced breast cancer and recurrent or metastatic breast cancer and has developed the Chinese expert consensus on the clinical diagnosis and treatment of advanced breast carcinoma (2018).</p>

oncology
Consistency of CSCO AI with Multidisciplinary Clinical Decision-Making Teams in Breast Cancer: A Retrospective Study

Weimin Xu,Xinyu Wang,Lei Yang,Muzi Meng,Chenyu Sun,Wanwan Li,Jia Li,Lu Zheng,Tong Tang,WenJun Jia,Xiao Chen

DOI: https://doi.org/10.2147/BCTT.S419433

2024-07-29

Abstract:Background: The Chinese Society of Clinical Oncology Artificial Intelligence System (CSCO AI) serves as a clinical decision support system developed utilizing Chinese breast cancer data. Our study delved into the congruence between breast cancer treatment recommendations provided by CSCO AI and their practical application in clinical settings. Methods: A retrospective analysis encompassed 537 breast cancer patients treated at the Second Affiliated Hospital of Anhui Medical University between January 2017 and December 2022. Proficient senior oncology researchers manually input patient data into the CSCO AI system. "Consistent" and "Inconsistent" treatment categories were defined by aligning our treatment protocols with the classification system in the CSCO AI recommendations. Cases that initially showed inconsistency underwent a second evaluation by the Multi-Disciplinary Treatment (MDT) team at the hospital. Concordance was achieved when MDTs' treatment suggestions were in the 'Consistent' categories. Results: An impressive 80.4% concurrence was observed between actual treatment protocols and CSCO AI recommendations across all breast cancer patients. Notably, the alignment was markedly higher for stage I (85.02%) and stage III (88.46%) patients in contrast to stage II patients (76.06%, P=0.023). Moreover, there was a significant concordance between invasive ductal carcinoma and lobular carcinoma (88.46%). Interestingly, triple-negative breast cancer (TNBC) exhibited a high concordance rate (87.50%) compared to other molecular subtypes. When contrasting MDT-recommended treatments with CSCO AI decisions, an overall 92.4% agreement was established. Furthermore, a logistic multivariate analysis highlighted the statistical significance of age, menstrual status, tumor type, molecular subtype, tumor size, and TNM stage in influencing consistency. Conclusion: In the realm of breast cancer treatment, the alignment between recommendations offered by CSCO AI and those from MDT is predominant. CSCO AI can be a useful tool for breast cancer treatment decisions.
Whole Brain Radiotherapy-Based Combined Modality Treatment of Brain Metastases from Non-Small Cell Lung Cancer: A Retrospective Analysis of Prognostic Factors

Zhenfei Xiang,Jun Chen,Huanle Zhang,Li Shen,Qichun Wei

DOI: https://doi.org/10.1159/000371501

2015-01-01

Oncology Research and Treatment

Abstract:Background: The prognostic factors for patients with brain metastases from non-small cell lung cancer treated with whole brain radiotherapy (WBRT)-based combined modality therapy were investigated. Materials and Methods: Out of 135 patients treated with WBRT, 47 (34.8%) received a radiation boost, 84 (62.2%) underwent systemic chemotherapy, and 39 (28.9%) were given epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs). Results: The mean survival time was 9.3 months, and the 1-year and 2-year survival rates were 46.3 and 16.1%, respectively. In univariate analysis, improved survival was associated with age < 60 years, no extracranial metastasis, Karnofsky performance score ≥ 70, ≥ 3 cycles of chemotherapy after diagnosis of brain metastases, combined treatment with EGFR-TKIs, and no metastases in the cerebellum. In multivariate analysis, the above prognostic factors maintained significance with the exception of age. In an additional analysis of the 58 patients with 1-3 brain metastases, combination of WBRT with radiation boost was associated with better survival. Conclusion: We confirm previously described prognostic factors. Moreover, we found the absence of cerebellar metastases to be an independent prognostic factor for favorable outcome.
Expert Consensus on the Diagnosis and Treatment of Bone Metastasis in Lung Cancer (2014 Version)

Yan Sun,Zhongzhen Guan,Meilin Liao,Xin Yu,Changli Wang,Jie Wang,Xiaohui Niu,Yuankai Shi,Xiuyi Zhi,Yunpeng Liu,Mengzhong Liu,Yiping Zhang,Yue Yang,Jingnan Shen,Gongyan Chen,Qinghua Zhou,Caicun Zhou,Qisen Guo,Lili Tang,Jianchun Duan,Jun Liang,Yingjian Zhang,Ying Cheng

DOI: https://doi.org/10.3779/j.issn.1009-3419.2014.02.01

2014-01-01

Abstract:Expert Consensus on the Diagnosis and Treatment of Bone Metastasis in Lung Cancer (2014 version) Yan SUN, Zhongzhen GUAN, Meilin LIAO, Xin YU, Changli WANG, Jie WANG, Xiaohui NIU, Yuankai SHI, Xiuyi ZHI, Yunpeng LIU, Mengzhong LIU, Yiping ZHANG, Yue YANG, Jingnan SHEN, Gongyan CHEN, Qinghua ZHOU, Caicun ZHOU, Qisen GUO, Lili TANG, Jianchun DUAN , Jun LIANG, Yingjian ZHANG, Ying CHENG 22 Cancer Hospital, Chinese Aacademy of Medical Sciences and Peking Union Medical College, Beijing 100021, China; SunYat-Sen University Cancer Center,Guangzhou 510060, China; Shanghai Chest Hospital, Shanghai, 200030, China; Department of psychiatry, Peking University Sixth Hospital, Beijing 100191, China; Department of Lung Cancer Surgery, Tianjin Cancer Hospital, Tianjin 300060, China; Department of oracic Medical Oncology, Beijing Cancer Hospital, Peking University, Beijing 100142, China; Department of Orthopedic Oncology Surgery, Beijing Jishuitan Hospital, Beijing 100035, China; Department of Medical Oncology, Cancer Hospital, Chinese Aacademy of Medical Sciences and Peking Union Medical College, Beijing 100021, China; Department of oracic Surgery, Beijing Lung Cancer Center, Beijing Xuanwu Hospital, Capital Medical University, Beijing 100053, China; Departmentof Medical Oncology, the First Hospital of China Medical University, Shenyang 110001, China; Department of Radiotherapy, Sun Yat-Sen University Cancer Center, Guangzhou 510060, China; Department of Chemotherapy, Zhejiang Cancer Hospital, Hangzhou 310022, China; Department of oracic Surgery, Beijing Cancer Hospital, Peking University, Beijing 100142, China; Department of Orthopedic Oncology Surgery, the First Affiliated Hospital Sun Yat-Sen University, Guangzhou 510080, China; Department of Medical Oncology, Haerbin Medical University Cancer Hospital, Haerbin 150081, China; Department of oracic Surgery, Tianjin Medical University General Hospital, Tianjin 300052, China; Departmentof Medical Oncology, Shanghai Pulmonary Hospital, Shanghai 200433, China; Department of Medical Oncology, Shandong Province cancer Hospital, Jinan 250117, China; Department of rehabilitation, Beijing Cancer Hospital, Peking University, Beijing 100142, China; Department of Medical Oncology, the A ated Hospital of Qingdao University, Qingdao 266003, China; Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai 200032, China; Department of Medical Oncology, Jilin Cancer Hospital, Changchun 130012, China DOI: 10.3779/j.issn.1009-3419.2014.02.01
Chinese expert consensus on the diagnosis and treatment of bone metastasis in lung cancer (2022 edition)

Jianchun Duan,Wenfeng Fang,Hairong Xu,Jinliang Wang,Yuan Chen,Yi Ding,Xiaorong Dong,Yun Fan,Beili Gao,Jie Hu,Yan Huang,Cheng Huang,Dingzhi Huang,Wenhua Liang,Lizhu Lin,Hui Liu,Zhiyong Ma,Meiqi Shi,Yong Song,Chuanhao Tang,Jialei Wang,Lifeng Wang,Yongfeng Wang,Zhehai Wang,Nong Yang,Yu Yao,Yan Yu,Qitao Yu,Hongmei Zhang,Jun Zhao,Mingfang Zhao,Zhengfei Zhu,Xiaohui Niu,Li Zhang,Jie Wang

DOI: https://doi.org/10.1016/j.jncc.2023.08.004

2023-08-19

Abstract:Lung cancer is the leading cause of cancer-related deaths worldwide. Bone is a common metastatic site of lung cancer, about 50% of bone metastatic patients will experience skeletal related events (SREs). SREs not only seriously impact the quality of life of patients, but also shorten their survival time. The treatment of bone metastasis requires multi-disciplinary therapy (MDT) and development of individualized treatment plan. In order to standardize the diagnosis and treatment of bone metastasis in lung cancer, the expert group of the MDT Committee of the Chinese Medical Doctor Association has developed the expert consensus on the diagnosis and treatment of lung cancer bone metastasis.
Guidelines of Chinese Society of Clinical Oncology (CSCO) on Diagnosis and Treatment of Breast Cancer (2020 version)

Zefei Jiang,Erwei Song,Xiaojia Wang,Haibo Wang,Xiang Wang,Jiong Wu,Yongmei Yin,Qingyuan Zhang,Jiayi Chen,Wenyan Che,Xiaoyuan Chen,Zhanhong Chen,Peifen Fu,Cuizhi Geng,Baoliang Guo,Chunfang Hao,Yingjian He,Feng Jin,Ning Liao,Nanlin Li,Jian Liu,Qiang Liu,Yunjiang Liu,Yueping Liu,Jie Ma,Jianyun Nie,Yueyin Pan,Chuangui Song,Tao Sun,Kun Wang,Shu Wang,Tao Wang,Xin Wang,Biyun Wang,Shusen Wang,Yongsheng Wang,Ling Xu,Min Yan,Ying Yan,Peng Yuan,Junlan Yang,Fan Zhang,Jun Zhang,Shaohua Zhang,Xuan Zeng,Jianbin Li,Fengrui Xu

DOI: https://doi.org/10.21037/tbcr-2020-2

2020-10-01

Translational Breast Cancer Research

Abstract:Guidelines of Chinese Society of Clinical Oncology (CSCO) on Diagnosis and Treatment of Breast Cancer (2020 version)
Treatment and survival of patients with small cell lung cancer and brain metastasis

Chi-Lu Chiang,Huai-Che Yang,Ying-Ting Liao,Yung-Hung Luo,Yuan-Hung Wu,Hsiu-Mei Wu,Yuh-Min Chen

DOI: https://doi.org/10.1007/s11060-023-04512-2

Abstract:Purpose: To elucidate treatment patterns and their outcomes in patients with small cell lung cancer (SCLC) and brain metastasis (BM). Methods: In this retrospective study, patients with SCLC and BM were stratified by treatment modality into three groups: those treated with systemic therapy only, those treated with stereotactic radiosurgery (SRS) and systemic therapy, and those treated with whole-brain radiotherapy (WBRT) and systemic therapy. The primary outcomes were overall survival (OS) and time to central nervous system progression (TTCP). Results: The analysis included 149 patients. After BM diagnosis, 48 patients (32.2%) received systemic therapy alone, 33 received SRS with systemic therapy, and 68 received WBRT with systemic therapy. The median OS and TTCP were 7.2 months and 8.7 months, respectively. Patients receiving WBRT with systemic therapy exhibited better intracranial control, but not better OS, than did the other patients. Key prognostic factors affecting OS were age, BM lesion count, chemotherapy, and immunotherapy. Notably, the Eastern Cooperative Oncology Group performance status and BM lesion count significantly influenced intracranial control in patients treated with SRS and systemic therapy. Conclusion: Although WBRT combined with systemic therapy offer better intracranial control in patients with SCLC and BM, this approach is not superior to the other approaches in terms of OS benefits. Emerging systemic therapies, such as immunotherapy, may be used as alternative or adjunctive treatments for specific patient populations. Further studies are warranted to refine treatment selection.
CACA Guidelines for Holistic Integrative Management of Breast Cancer

Daiming Fan,Tao Jiang,Wenbin Ma,Chuanlu Jiang,Yongping You,Ying Mao,Xiaoguang Qiu,Chunsheng Kang,Gang Li,Qing Mao,Xuejun Yang,Zhiyong Qin,Zhixiong Liu,Weimin Wang,Xinting Wei,Wenbin Li,Yunhui Liu,Rutong Yu,Xinguang Yu,Dezhi Kang,Yonggao Mou,Lei Wang,Wei Zhang,Zhaoshi Bao,Ruichao Chai,Baoshi Chen,Xing Fan,Shengyu Fang,Guanzhang Li,Lianwang Li,Shouwei Li,Xing Liu,Yanwei Liu,Xia Shan,Liang Wang,Yinyan Wang,Yu Wang,Zheng Wang,Zhiliang Wang,Chenxing Wu,Wei Yan,Pei Yang,Gan You,Chuanbao Zhang,Zhong Zhang,Zheng Zhao

DOI: https://doi.org/10.1007/s44178-022-00007-8

2022-01-01

Holistic Integrative Oncology

Abstract:Glioma of the brain is a kind of tumor originating from neuroglial cells. It is the most common primary intracranial tumor, accounting for ~ 30% of all central nervous system tumors and 80% of malignant brain tumors. Glioma is characterized by high disability and recurrence rates. The disease seriously threatens the life of patients, affects their quality of life, and brings a heavy economic and psychological burden to patients, families, and society. With the progression of molecular genetic testing technology and the completion of various clinical trials, the classification scheme for glioma is increasingly well established. Diagnosis and treatment regimens, including traditional and new regimens, are becoming increasingly specialized and standardized. The purpose is to develop a clinical diagnosis and treatment guideline for glioma in the Chinese population suitable for Chinese doctors and the general population based on domestic and international glioma research progress. Thus, domestic practitioners in the field can obtain current information and provide better service to patients with glioma, promoting the development of domestic clinical medicine and basic research on glioma.
A Network Meta-Analysis of Curative Effect of Different Treatment Methods on Patients with Brain Metastasis of Breast Cancer

Anhao Wu,Fang Zhang,Xin Yang,Yang Liu,Mingjian Tan,Yafang Lai,Yang Zhang

DOI: https://doi.org/10.1097/md.0000000000030392

IF: 1.6

2022-01-01

Medicine

Abstract:Background: Breast cancer (BC) is a malignant tumor with the highest incidence rate worldwide, and its incidence of breast cancer brain metastases is increased in recent years. Although significant progress has been made in the systematic treatment of BC that of breast cancer brain metastases is still very difficult. Organically integrating local and systemic therapies remains an urgent problem to be solved. In this study, a network meta-analysis was performed to collect the treatment effects of different treatment measures on patients with BC brain metastasis in recent years, evaluate and screen the current best clinical treatment scheme, and assist doctors in formulating clinical treatment schemes. Methods: Keywords were used to search databases, such as the Chinese Journal Full-text Database, VIP Chinese Science and Technology Journal Full-text Database (VP-CSJFD), Wanfang Data Journal Paper Resources (Wangfang), PubMed, the Cochrane Library, and EMBASE. The retrieval period was from the establishment of each database to February 2022. Qualified randomized controlled studies were screened according to the inclusion and exclusion criteria, and Stata 16 software was adopted for mesh meta-analysis of binary variable data. Using R4 0.2 software, and calling GeMTC and JAGS packages in R software, the Bayesian network model analysis of survival data was completed. Conclusion: Combined with overall response rate, disease control rate, and overall survival, whole-brain radiation therapy + 3-dimensional conformal radiation therapy + Che may be the intervention measure with the highest objective remission rate for patients with brain metastasis of BC, besides, it may also be the intervention measure of the highest disease control rate in patients after treatment. In contrast, WBRT + Che may be the intervention with the lowest overall survival risk ratio after treatment.
Breast cancer brain metastasis: Current evidence and future directions

Hongna Sun,Junnan Xu,Shuang Dai,Yiwen Ma,Tao Sun

DOI: https://doi.org/10.1002/cam4.5021

IF: 4.711

2022-07-19

Cancer Medicine

Abstract:A portion of cells at the primary site acquired invasive properties by EMT. Invasive cancer cells intravasate into the bloodstream, survive, and arrest the circulatory system. Then these cells extravasate through transendothelial migration, colonize, and form metastatic brain lesions. BBB plays a critical role in ensuring normal brain function. However, as the development of primary or metastatic tumors in the brain, BBB becomes disrupted, and is altered to BTB. At last, new, and aberrant vessels grow during tumor progression. Breast cancer is the most common cancer in women and the second leading cause of cancer‐related deaths after lung cancer. Metastasis of the central nervous system is a terrible event for breast cancer patients, affecting their survival and quality of life. Compared with hormone receptor‐positive/human epidermal growth factor receptor 2‐negative breast cancer patients, brain metastases are more likely to affect patients with triple‐negative breast cancer and human epidermal growth factor receptor 2‐positive breast cancer. The treatment of breast cancer has improved greatly in the last two decades. However, brain metastases from breast cancer remain the leading cause of morbidity and mortality. Patients with breast cancer brain metastasis have been in an inferior position due to the lack of clinical research in this field, and they are often explicitly excluded from almost all clinical trials. The occurrence and progression of brain metastases will result in severe cognitive impairment and adverse physical consequences, so we must have a good understanding of the molecular mechanisms of breast cancer brain metastasis. In this article, we have retrieved the latest literature of molecules and pathways associated with breast cancer brain metastasis, summarized common therapy strategies, and discussed the prospects and clinical implications of targeting the molecules involved.

oncology
National Consensus in China on Diagnosis and Treatment of Patients with Advanced Breast Cancer.

Binghe Xu,Xichun Hu,Zefei Jiang,Huiping Li,Jiayi Chen,Shude Cui,Qing Li,Ning Liao,Donggeng Liu,Jian Liu,Jinsong Lu,Kunwei Shen,Tao Sun,Yuee Teng,Zhongsheng Tong,Shulian Wang,Xiang Wang,Xiaojia Wang,Yongsheng Wang,Jiong Wu,Peng Yuan,Pin Zhang,Qingyuan Zhang,Hong Zheng,Da Pang,Guosheng Ren,Zhimin Shao,Zhenzhou Shen,Erwei Song,Santai Song

DOI: https://doi.org/10.3978/j.issn.2305-5839.2015.09.47

IF: 3.616

2015-01-01

Annals of Translational Medicine

Abstract:The recently available guidelines on the management of advanced breast cancer (ABC) organized by Chinese Anti-Cancer Association, Committee of Breast Cancer Society (CACA-CBCS) do not elucidate ABC in details. To instruct clinicians in treatment of ABC, a Chinese expert consensus meeting on diagnosis and treatment of ABC was held in June 2014 and a consensus is developed. The following consensus provides the level of evidence and supporting documents for each recommendation, and introduces research topics to be urgently addressed. Notably, the consensus on diagnosis and treatment of ABC in China is developed to be applied nationwide. In different areas, multidisciplinary treatment (MDT) tailored to the each patient and the disease itself should be applied based on the basic principles of modern oncology.
Expert consensus on the clinical diagnosis and targeted therapy of HER2 breast cancer (2023 edition)

Jianbin Li,Xiaojia Wang,Shusen Wang,Shu Wang,Tao Wang,Yueping Liu,Cuizhi Geng,Feng Jin,Yongmei Yin,Qingyuan Zhang,Erwei Song,Jiong Wu,Zefei Jiang,,,

DOI: https://doi.org/10.21037/tbcr-22-48

2022-10-01

Translational Breast Cancer Research

Abstract:Expert consensus on the clinical diagnosis and targeted therapy of HER2 breast cancer (2023 edition)
Nursing perspective of the expert consensus on diagnosis and treatment of integrated Chinese and Western medicine in lung cancer

Jing Zhang,Tao Ma,Shuhong Liu,Yan Zhao,Ling Tang

DOI: https://doi.org/10.4103/jin.jin_61_21

2022-01-01

Journal of Integrative Nursing

Abstract:Lung cancer is a malignant tumor with the highest incidence and mortality in China, which seriously affects the quality of life of patients. Traditional Chinese medicine (TCM) plays a unique advantage in the treatment and rehabilitation of lung cancer. In order to standardize TCM diagnosis and treatment and disease management of clinical medical workers, the Chinese Association of Integrative Medicine issued the “Expert Consensus on the Diagnosis and Treatment of Lung Cancer by Integrated Traditional Chinese and Western Medicine” in August 2021. Experts' recommendations were made on the clinical staging and syndrome differentiation and classification of lung cancer, characteristic TCM therapies, and nursing care of integrated traditional Chinese and Western medicine. This article interpreted the Consensus on the above aspects from a nursing perspective, hoping to provide references for clinical medical workers in the treatment and nursing care of lung cancer.
Impact of Multidisciplinary Team on the Pattern of Care for Brain Metastasis from Breast Cancer

Fei Xu,Dan Ou,Weixiang Qi,Shubei Wang,Yiming Han,Gang Cai,Lu Cao,Cheng Xu,Jia-Yi Chen

DOI: https://doi.org/10.3389/fonc.2023.1160802

IF: 4.7

2023-01-01

Frontiers in Oncology

Abstract:Purpose The aim of this study was to explore how a multidisciplinary team (MDT) affects patterns of local or systematic treatment.Methods We retrospectively reviewed the data of consecutive patients in the breast cancer with brain metastases (BCBM) database at our institution from January 2011 to April 2021. The patients were divided into an MDT group and a non-MDT group.Results A total of 208 patients were analyzed, including 104 each in the MDT and non-MDT groups. After MDT, 56 patients (53.8%) were found to have intracranial "diagnosis upgrade". In the matched population, patients in the MDT group recorded a higher proportion of meningeal metastases (14.4% vs. 4.8%, p = 0.02), symptomatic tumor progression (11.5% vs. 5.8%, p = 0.04), and an increased number of occurrences of brain metastases (BM) progression (p < 0.05). Attending MDT was an independent factor associated with =2 courses of intracranial radiotherapy (RT) [odds ratio (OR) 5.4, 95% confidence interval (CI): 2.7-10.9, p < 0.001], novel RT technique use (7.0, 95% CI 3.5-14.0, p < 0.001), and prospective clinical research (OR 5.7, 95% CI 2.4-13.4, p < 0.001).Conclusion Patients with complex conditions are often referred for MDT discussions. An MDT may improve the qualities of intracranial RT and systemic therapy, resulting in benefits of overall survival for BC patients after BM. This encourages the idea that treatment recommendations for patients with BMBC should be discussed within an MDT.
Guidelines of Chinese Society of Clinical Oncology (CSCO) on Diagnosis and Treatment of Breast Cancer: an appraisal

Rani Chudasama,Mary Anne Fenton,Don S. Dizon

DOI: https://doi.org/10.21037/tbcr-2020-3

2020-10-01

Translational Breast Cancer Research

Abstract:Guidelines of Chinese Society of Clinical Oncology (CSCO) on Diagnosis and Treatment of Breast Cancer: an appraisal
Expert consensus on multidisciplinary therapy of colorectal cancer with lung metastases (2019 edition)

Jian Li,Ying Yuan,Fan Yang,Yi Wang,Xu Zhu,Zhenghang Wang,Shu Zheng,Desen Wan,Jie He,Jianping Wang,Yi Ba,Chunmei Bai,Li Bai,Wei Bai,Feng Bi,Kaican Cai,Muyan Cai,Sanjun Cai,Gong Chen,Keneng Chen,Lin Chen,Pengju Chen,Pan Chi,Guanghai Dai,Yanhong Deng,Kefeng Ding,Qingxia Fan,Weijia Fang,Xuedong Fang,Fengyi Feng,Chuangang Fu,Qihan Fu,Yanhong Gu,Yulong He,Baoqing Jia,Kewei Jiang,Maode Lai,Ping Lan,Enxiao Li,Dechuan Li,Jin Li,Leping Li,Ming Li,Shaolei Li,Yexiong Li,Yongheng Li,Zhongwu Li,Xiaobo Liang,Zhiyong Liang,Feng Lin,Guole Lin,Hongjun Liu,Jianzhong Liu,Tianshu Liu,Yunpeng Liu,Hongming Pan,Zhizhong Pan,Haiping Pei,Meng Qiu,Xiujuan Qu,Li Ren,Zhanlong Shen,Weiqi Sheng,Chun Song,Lijie Song,Jianguo Sun,Lingyu Sun,Yingshi Sun,Yuan Tang,Min Tao,Chang Wang,Haijiang Wang,Jun Wang,Shubin Wang,Xicheng Wang,Xishan Wang,Ziqiang Wang,Aiwen Wu,Nan Wu,Lijian Xia,Yi Xiao,Baocai Xing,Bin Xiong,Jianmin Xu,Jianming Xu,Nong Xu,Ruihua Xu,Zhongfa Xu,Yue Yang,Hongwei Yao,Yingjiang Ye,Yonghua Yu,Yueming Yu,Jinbo Yue,Jingdong Zhang,Jun Zhang,Suzhan Zhang,Wei Zhang,Yanqiao Zhang,Zhen Zhang,Zhongtao Zhang,Lin Zhao,Ren Zhao,Fuxiang Zhou,Jian Zhou,Jing Jin,Jin Gu,Lin Shen

DOI: https://doi.org/10.1186/s13045-019-0702-0

IF: 28.5

2019-01-01

Journal of Hematology & Oncology

Abstract:The lungs are the second most common site of metastasis for colorectal cancer (CRC) after the liver. Rectal cancer is associated with a higher incidence of lung metastases compared to colon cancer. In China, the proportion of rectal cancer cases is around 50%, much higher than that in Western countries (nearly 30%). However, there is no available consensus or guideline focusing on CRC with lung metastases. We conducted an extensive discussion and reached a consensus of management for lung metastases in CRC based on current research reports and the experts’ clinical experiences and knowledge. This consensus provided detailed approaches of diagnosis and differential diagnosis and provided general guidelines for multidisciplinary therapy (MDT) of lung metastases. We also focused on recommendations of MDT management of synchronous lung metastases and initial metachronous lung metastases. This consensus might improve clinical practice of CRC with lung metastases in China and will encourage oncologists to conduct more clinical trials to obtain high-level evidences about managing lung metastases.
Favorable prognosis of breast cancer brain metastases patients with limited intracranial and extracranial metastatic lesions

Wei Shi,Yang Li,Hua Sun,Li Zhang,Jin Meng,Xiaofang Wang,Xingxing Chen,Xiaomeng Zhang,Xin Mei,Jinli Ma,Miao Mo,Changming Zhou,Fei Liang,Zhimin Shao,Zhen Zhang,Xiaomao Guo,Xiaoli Yu,Zhaozhi Yang

DOI: https://doi.org/10.1186/s13014-023-02293-6

IF: 4.309

2023-07-03

Radiation Oncology

Abstract:Breast cancer brain metastases (BCBM) are highly heterogenous with widely differing survival. The prognosis of the oligometastatic breast cancer (BC) patients with brain metastases (BM) has not been well studied. We aimed to investigate the prognosis of BCBM patients with limited intracranial and extracranial metastatic lesions.

oncology,radiology, nuclear medicine & medical imaging
Breast Cancer Brain Metastasis: A Comprehensive Review

Akshara S Raghavendra,Nuhad K Ibrahim

DOI: https://doi.org/10.1200/OP.23.00794

Abstract:The mechanisms underlying breast cancer brain metastasis (BCBM) development are complex, and its clinical presentation varies depending on the number, location, and size of brain metastases. Common symptoms include headache, neurologic deficits, and seizures. Diagnosis of BCBM typically relies on neuroimaging techniques, such as magnetic resonance imaging and computed tomography scans. Local therapies, such as surgery and stereotactic radiosurgery, can be used to control tumor growth and relieve symptoms. Whole-brain radiotherapy has been a mainstay of treatment for BCBM, but its use has been associated with cognitive decline. Systemic therapy with chemotherapy and targeted agents plays an increasingly important role in the management of BCBM. Novel agents, such as human epidermal growth factor receptor 2 (HER2)-targeted therapies and tyrosine kinase inhibitors, have shown promising results in improving survival for patients with HER2-positive and triple-negative BCBM. This comprehensive review synthesizes current knowledge, clinical insights, and evolving paradigms to provide a robust understanding and roadmap for optimizing the diagnosis and management of BCBM.

CSCO expert consensus on the diagnosis and treatment of breast cancer brain metastasis

Factors Prognostic for Brain Metastases from Colorectal Cancer: A Single-Center Experience in China.

Chinese expert consensus statement on the clinical diagnosis and treatment of breast cancer bone metastasis and bone related disease

Chinese expert consensus on the clinical diagnosis and treatment of advanced breast cancer (2018)

Consistency of CSCO AI with Multidisciplinary Clinical Decision-Making Teams in Breast Cancer: A Retrospective Study

Whole Brain Radiotherapy-Based Combined Modality Treatment of Brain Metastases from Non-Small Cell Lung Cancer: A Retrospective Analysis of Prognostic Factors

Expert Consensus on the Diagnosis and Treatment of Bone Metastasis in Lung Cancer (2014 Version)

Chinese expert consensus on the diagnosis and treatment of bone metastasis in lung cancer (2022 edition)

Guidelines of Chinese Society of Clinical Oncology (CSCO) on Diagnosis and Treatment of Breast Cancer (2020 version)

Treatment and survival of patients with small cell lung cancer and brain metastasis

CACA Guidelines for Holistic Integrative Management of Breast Cancer

A Network Meta-Analysis of Curative Effect of Different Treatment Methods on Patients with Brain Metastasis of Breast Cancer

Breast cancer brain metastasis: Current evidence and future directions

National Consensus in China on Diagnosis and Treatment of Patients with Advanced Breast Cancer.

Expert consensus on the clinical diagnosis and targeted therapy of HER2 breast cancer (2023 edition)

Nursing perspective of the expert consensus on diagnosis and treatment of integrated Chinese and Western medicine in lung cancer

Impact of Multidisciplinary Team on the Pattern of Care for Brain Metastasis from Breast Cancer

Guidelines of Chinese Society of Clinical Oncology (CSCO) on Diagnosis and Treatment of Breast Cancer: an appraisal

Expert consensus on multidisciplinary therapy of colorectal cancer with lung metastases (2019 edition)

Favorable prognosis of breast cancer brain metastases patients with limited intracranial and extracranial metastatic lesions

Breast Cancer Brain Metastasis: A Comprehensive Review